t-GMP activators comprise a diverse group of chemical compounds that indirectly enhance t-GMP's functional activity through modulation of cyclic nucleotide levels and related signaling pathways. Forskolin, by elevating intracellular cAMP, activates PKA, which can phosphorylate substrates involved in t-GMP signaling, thus enhancing t-GMP's functional activity. Similarly, IBMX and Rolipram, as inhibitors of phosphodiesterases, prevent the breakdown of cyclic nucleotides, leading to an accumulation of cAMP (in the case of Rolipram) and both cAMP and cGMP (for IBMX). This accumulation indirectly augments t-GMP activity by increasing its local concentration and promoting its signaling pathways. Furthermore, PDE5 inhibitors like Sildenafil, Vardenafil, and Tadalafil specifically increase cGMP levels, indirectly activating t-GMP through enhanced cGMP-dependent protein kinase signaling pathways. This effect is mirrored by Zaprinast, which selectively inhibits PDE5, leading to increased cGMP levels and subsequent activation of cGMP-dependent pathways related to t-GMP.
The influence on t-GMP activity is further extended by compounds that modulate both cAMP and cGMP levels. Vinpocetine and Papaverine, by inhibiting PDE1, lead to an increase in both these cyclic nucleotides, providing a synergistic enhancement of t-GMP activity through the activation of both cAMP and cGMP-dependent signaling pathways. Cilostazol and Milrinone, as selective PDE3 inhibitors, elevate cAMP levels, which indirectly activates t-GMP through PKA-mediated signaling pathways and the potential cross-talk between cAMP and cGMP signaling. Dipyridamole, with its ability to inhibit various phosphodiesterases, also contributes to the increased levels of cyclic nucleotides, further potentiating t-GMP's functional activity. Collectively, these t-GMP activators, through their targeted effects on cyclic nucleotide levels and signaling pathways, facilitate the enhancement of t-GMP mediated functions, highlighting the intricate interplay between different cellular signaling molecules and pathways in regulating protein activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Activates adenylate cyclase, increasing cAMP levels. Elevated cAMP activates PKA, enhancing t-GMP activity by influencing downstream effectors in t-GMP signaling pathways. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
A non-selective inhibitor of phosphodiesterases. Prevents breakdown of cAMP and cGMP, leading to accumulation of cGMP, which enhances t-GMP activity by promoting its signaling pathways. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Selectively inhibits PDE5, increasing cGMP levels. Elevated cGMP enhances t-GMP activity by activating cGMP-dependent protein kinases (PKG) that influence t-GMP-related pathways. | ||||||
Vardenafil | 224785-90-4 | sc-362054 sc-362054A sc-362054B | 100 mg 1 g 50 g | $526.00 $735.00 $16653.00 | 7 | |
Functions similarly to Sildenafil by inhibiting PDE5 and increasing cGMP levels. This accumulation activates t-GMP via cGMP-dependent signaling mechanisms. | ||||||
Tadalafil | 171596-29-5 | sc-208412 | 50 mg | $180.00 | 13 | |
Another PDE5 inhibitor that elevates cGMP levels, indirectly activating t-GMP through enhanced cGMP-dependent protein kinase signaling pathways. | ||||||
Cilostazol | 73963-72-1 | sc-201182 sc-201182A | 10 mg 50 mg | $109.00 $322.00 | 3 | |
Inhibits PDE3, increasing cAMP levels. Elevated cAMP indirectly activates t-GMP by stimulating PKA, which may modulate proteins in pathways linked to t-GMP activity. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
A selective PDE4 inhibitor that increases intracellular cAMP levels. This elevation enhances t-GMP activity through PKA-mediated signaling pathways. | ||||||
Vinpocetine | 42971-09-5 | sc-201204 sc-201204A sc-201204B | 20 mg 100 mg 15 g | $55.00 $214.00 $2400.00 | 4 | |
Inhibits PDE1, leading to increased levels of both cAMP and cGMP. This dual elevation synergistically enhances t-GMP activity by activating cAMP and cGMP-dependent pathways. | ||||||
Dipyridamole | 58-32-2 | sc-200717 sc-200717A | 1 g 5 g | $31.00 $102.00 | 1 | |
Inhibits various phosphodiesterases, increasing cAMP and cGMP levels. The resultant elevation in cGMP enhances t-GMP activity via cGMP-dependent protein kinases. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $165.00 $697.00 | 7 | |
Selectively inhibits PDE3, increasing cAMP levels. This increase indirectly enhances t-GMP activity through PKA-mediated pathways and cross-talk between cAMP and cGMP signaling. | ||||||